Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 158

1.

Quantitation of marrow disease in neuroblastoma by real-time reverse transcription-PCR.

Cheung IY, Cheung NK.

Clin Cancer Res. 2001 Jun;7(6):1698-705.

3.

GD2 synthase: a new molecular marker for detecting neuroblastoma.

Lo Piccolo MS, Cheung NK, Cheung IY.

Cancer. 2001 Aug 15;92(4):924-31.

PMID:
11550167
4.

Analysis of GD2/GM2 synthase mRNA as a biomarker for small cell lung cancer.

Chen LC, Brown AB, Cheung IY, Cheung NK, Kris MG, Krug LM.

Lung Cancer. 2010 Feb;67(2):216-20. doi: 10.1016/j.lungcan.2009.04.009.

PMID:
19457569
6.
8.

Comparison of immunocytochemistry, real-time quantitative RT-PCR and flow cytometry for detection of minimal residual disease in neuroblastoma.

Ifversen MR, Kågedal B, Christensen LD, Rechnitzer C, Petersen BL, Heilmann C.

Int J Oncol. 2005 Jul;27(1):121-9.

PMID:
15942651
9.

Early molecular response of marrow disease to biologic therapy is highly prognostic in neuroblastoma.

Cheung IY, Lo Piccolo MS, Kushner BH, Cheung NK.

J Clin Oncol. 2003 Oct 15;21(20):3853-8.

PMID:
14551304
10.

PHOX2B is a novel and specific marker for minimal residual disease testing in neuroblastoma.

Stutterheim J, Gerritsen A, Zappeij-Kannegieter L, Kleijn I, Dee R, Hooft L, van Noesel MM, Bierings M, Berthold F, Versteeg R, Caron HN, van der Schoot CE, Tytgat GA.

J Clin Oncol. 2008 Nov 20;26(33):5443-9. doi: 10.1200/JCO.2007.13.6531.

PMID:
18838715
11.

ppGalNAc-T13: a new molecular marker of bone marrow involvement in neuroblastoma.

Berois N, Blanc E, Ripoche H, Mergui X, Trajtenberg F, Cantais S, Barrois M, Dessen P, Kågedal B, Bénard J, Osinaga E, Raguénez G.

Clin Chem. 2006 Sep;52(9):1701-12. Erratum in: Clin Chem. 2006 Dec;52(12):2315-8.

12.
13.

Real-time RT-PCR of tyrosine hydroxylase to detect bone marrow involvement in advanced neuroblastoma.

Pession A, Libri V, Sartini R, Conforti R, Magrini E, Bernardi L, Fronza R, Olivotto E, Prete A, Tonelli R, Paolucci G.

Oncol Rep. 2003 Mar-Apr;10(2):357-62.

PMID:
12579272
15.
16.

Outcome prediction by molecular detection of minimal residual disease in bone marrow for advanced neuroblastoma.

Horibe K, Fukuda M, Miyajima Y, Matsumoto K, Kondo M, Inaba J, Miyashita Y.

Med Pediatr Oncol. 2001 Jan;36(1):203-4.

PMID:
11464885
17.

Real-time analysis of tyrosine hydroxylase gene expression: a sensitive and semiquantitative marker for minimal residual disease detection of neuroblastoma.

Lambooy LH, Gidding CE, van den Heuvel LP, Hulsbergen-van de Kaa CA, Ligtenberg M, Bökkerink JP, De Abreu RA.

Clin Cancer Res. 2003 Feb;9(2):812-9.

18.

Potential application of ELAVL4 real-time quantitative reverse transcription-PCR for detection of disseminated neuroblastoma cells.

Swerts K, De Moerloose B, Dhooge C, Vandesompele J, Hoyoux C, Beiske K, Benoit Y, Laureys G, Philippé J.

Clin Chem. 2006 Mar;52(3):438-45.

20.

Molecular detection of dopamine decarboxylase expression by means of reverse transcriptase and polymerase chain reaction in bone marrow and peripheral blood: utility as a tumor marker for neuroblastoma.

Bozzi F, Luksch R, Collini P, Gambirasio F, Barzanò E, Polastri D, Podda M, Brando B, Fossati-Bellani F.

Diagn Mol Pathol. 2004 Sep;13(3):135-43.

PMID:
15322424
Items per page

Supplemental Content

Support Center